Research Analysts Issue Forecasts for Zoetis FY2025 Earnings

Zoetis Inc. (NYSE:ZTS) – Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for Zoetis in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $6.09 for the year, down from their previous estimate of $6.19. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.39 EPS, FY2025 earnings at $6.09 EPS, FY2026 earnings at $6.82 EPS, FY2027 earnings at $7.46 EPS, FY2027 earnings at $7.46 EPS, FY2028 earnings at $8.10 EPS and FY2028 earnings at $8.10 EPS.

Other analysts also recently issued reports about the stock. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Piper Sandler reduced their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $214.90.

Zoetis Trading Down 4.5 %

NYSE:ZTS opened at $157.54 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s 50-day simple moving average is $168.51 and its 200-day simple moving average is $178.79. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The stock has a market capitalization of $71.08 billion, a PE ratio of 29.61, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. increased its holdings in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis during the 4th quarter worth about $30,000. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the 3rd quarter worth about $31,000. Finally, First Personal Financial Services bought a new stake in shares of Zoetis during the 3rd quarter worth about $33,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.